OPN1SW and acute lymphoblastic leukemia: An ongoing phase 2 study (NCT02744768) is evaluating the potential for a chemotherapy-free induction-consolidation frontline regimen of dasatinib combined with blinatumomab in obtaining an MRD response in patients with newly diagnosed Ph+ BCP-ALL.